Cardiovascular disease in the literature: A selection of recent original research papers
- 39 Downloads
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.N Engl J Med.2019;380:752-62
Background: Inflammation is a causal factor in the development and progression of coronary artery disease (CAD). Low-dose methotrexate (LDM) is an inexpensive and effective anti-inflammatory agent that is widely used for the treatment of rheumatoid arthritis and other inflammatory diseases. Ridker et al from the Brigham and Women’s Hospital, Boston randomized in a double-blind fashion after a run-in period, 4786 patients with diabetes mellitus or metabolic syndrome who have prior myocardial infarction or multivessel to LDM or placebo. All participants received 1 mg of folate daily. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for unstable angina.
Findings:At the end of the trial (median follow-up of 2.3 years) 21% of the LDM group and 22% of placebo group had permanently discontinued study drug. The...
Dr. Hage reports research grant support from Astellas pharma and GE Healthcare.